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A Global Survey Yeast Susceptibility to 
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Fluconazole is currently the azole antifungal drug most used for the 
treatment of yeast mfections because of its high rate of efficacy, low 
toxicity and simplicity of a b t r a t i o n .  As a result of the wide use 
of fluconazole, particularly as prophylaxis and treatment of oropha- 
ryngeal candidosis in HN-infected patients, changes in the suscepti- 
blity of some strains of Candida albirans and the emergence of other 
species less susceptible in vitro such as Candid0 ktusk and Tomlopsis 
(Candida) glabratu have occurred. The significance of these effects on 
the course of the disease is controversial. 
Stukes of susceptibility to Flucon&ole have been pubhhed by 
many laboratories in several countries, most of them h m  the USA. 
In general terms the results seem to be similar but there are Wer- 
ences in methodology and procedure. 
In a multicentre survey of in vitro antifungal resistance in yeasts of 
medical importance isolated form Spanish patients, the susceptibility 
to fluconazole was 90.2%; only 4% of C. albiram strains were not 
susceptible. Most resistance was seen in C. glabrata and C. guillier- 
mondii. AU C. tropicalis were susceptible to fluconazole. Conclusions 
of thts study were that resistance to antifungals is very low in Spain 
and it is related to a few non-albicanc species. 
Glauser et al conducted a multicentre study in 23 Werent coun- 
tries with 2231 consecutively isolated Candida strains in whch a 
fluconazole difFusion assay was performed. The results of this study 
showed the 97.1% of C. albicans strains were susceptible to this an- 
tifungal. When other species of Candida were studied the suscepti- 
bility was lower (83.4%). The results of the difLsion test correlated 
with MICs (NCCLS proposals) for susceptible or intermediate saains 
when the zones of inhibition were 18-25 mm. 
These results suggested a low in vitro world-wide resistance of 
Candida albirnns to fluconazole and variable susceptibility depending 
on the other Candida species considered. 
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In a group of 14 HIV-infected persons, mean loss of telomere length 
in PBMC over 3 to 9 years was sigmficantly increased compared 
to mean loss of TRF length in 7 healthy contmls. Loss of telom- 
ere length in HIV infection was found exdusively in CD8+ T cells 
and not in CD4+ T cells. Loss of telomere length could not be 
explained by differential telomerase activity. This provides evidence 
that turnover in the course of HIV-1 infection can be increased con- 
siderably in CD8+ T cells, but not in CD4+ T cells. T ~ I S  implies 
that CD4+ T cell decline in HIV-1 infection might be caused by 
&bition of CD4+ T cell renewal. To further study T cell renewal 
capacity and kinetics we evaluated the repopulation of CD4+ and 
CD8+ T cell subsets and their functional improvement during the 
first 36 weeks of treatment with ritonavir, 3TC and zidovudine that 
induced a strong and persistent reduction of the plasma and lym- 
phoid viral load. A strikingly distinct kinetics for CD4+ CD45RO+ 
and RA+ cells was observed. CD45RO+ cell repopulation followed 
a biphasic pattern, with a steep increase in the first 5 weeks and a 
gradual slow increase the following months. In contrast, the naive 
CD62L+ cells over the follow up period showed a slow and gradual 
increase with a mean increase of 10’ cells per day. In addition, a sus- 
tained improvement of T cell function was seen in the patients. Our 
results demonstrate that immunereconstitution following anti-viral 
therapy may be slow and may not readily reach normal levels of 
immunocompetence. 
The Impact of potent antiretroviral treatment on 
viral burden and immune depletion in lymphatic 
tissues 
A.T. Haase. Department dMicrobioloa, University ofMinnerota, 
Minneapolis, M N ,  U S A  
Quantitative image analysis of sections of lymphatic tissues (LT) after 
in situ hybridization to reveal viral RNA, or immunohistochemisay 
to identlfy subsets of CD4+ T cells af50rd.s new opportunities to 
understand the pathogenesis of infection and response to treatment. 
I wiU describe the results of recent experiments on the response to 
combinations of antiretroviral therapy in LT that define the kinet- 
ics and magnitude of this response. I wiU also describe the rate of 
CD4+ T cell replacement that suggests a “Red Queen” mechanism 
of immune depletion in HIV-1 infection. 
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4th generation cephalosporins: 
Microbiological rationale and clinical 
perspectives 
P-lactamase-mediated resistance in hospital 
pathogens 
R.N. Jones. University OfIowa, IA, USA 
Resistance in Gram-negative bacteria is frequently mediated by 
/3-lactamase production. The four major p u p s  currently recog- 
nised on the basis of amino acid sequence (A to D) include 3 with a 
serine active site (A, C and D). Class A includes the common TEM 
enzymes, class B the metallo B-lactamases which coder resistance 
to carbapenems, class C the AmpC chromosomal cephalosporinases 
and class D the OXA and PSE enzymes which have p e n i c b  as 
the preferred substrate. Of particular concern are inducible AmpC 
/3-lactamases, found in Enterobacter, Citrobacter, Serratia, Pseudomom, 
Morganella and Providenn'a spp. and which confer resistance (sta- 
bly de-repressed mutants) to 3d generation cephalosporins (3GCs). 
These pathogens are fiequent causes of nosocomial infection and 
pose an enormous therapeutic challenge to the chician. Resistance 
can emerge on treatment. Infections caused by Enterobacter have in- 
creased during the 1990s: thls pathogen was responsible for 6.3% of 
all mfections in a US survey conducted in 1994, and is the fourth 
most prevalent cause of nosocormal RTI. In Europe and the Far East 
(1987-91), up to 40% of isolates of Enterobncrer cloarae and Citrob- 
jeundii produced stably depressed AmpC /3-lactamases. T ~ I S  increase 
in resistance to 3 GCs has been correlated with increased use of 
some broad spectrum antimicrobials such as ceftazidime. Both 3GCs 
and carbapenems are potent inducers of AmpC, but 4th generation 
cephalosporins such as cefpirome and cefepime have low induction 
potential and &ty for the enzyme. In addition, their high mem- 
brane penetration rates and /3-lactamase stability make them valuable 
treatment options as resistance increases in the hospital environment. 
Extended-spectrum /3-lactamases are also increasing in prevalence. 
Changing epidemiology of severe nosocomial 
infections 
D. Pittet. Hopital Cantonal Universitaire, Geneva, Switzerland 
In the setting of the ICU, data on the epidemiology of severe infec- 
tion are used to monitor the effect of preventive measures and pol- 
icy changes. The chance of contracting infection correlates with MI- 
ious risk factors including length of stay, antibacterial usage, catheter- 
isation, mechanical ventilation and use of invasive devices. Infection 
can be classified as community- or hospital-acquired, and early or 
late in onset. Most early onset infection (5 4 days) is associated with 
S. pneumoniae or other streptococci, H. Injuenzae, enterobacteria or 
MSSA. Late onset infection (r 4 days) is associated with Enferoboc- 
ter spp., Smatia spp., Pseudomom spp., Acinetobacter spp., enterococci, 
MRSA and fungi, and is consequently more &cult to treat. A twelve 
year (1980-1992) study including 260,834 patients in the USA has 
confirmed the increase in Gram-positive pathogens at the expense 
of Gram-negatives, particularly as causal agents of bacteremia, al- 
though some new and d&cult-treat Gram-negatives are emerging, 
e.g. Srenotrophomom. Treatment of severe nosocormal mfections re- 
mains mostly empirical, and with the increase of resistance to existing 
agents, alternatives are needed. Carbapenems are powerful antibacte- 
rials, but the emergence of metallo /3-lactamases is of concern. 4'h 
generation cephalosporins, e.g. cefpirome and cefipime, hold promise 
in view of their broad spectrum, stability to most 6-lactamases and 
enhanced Gram-positive activity. Carefully designed cllnical trials are 
mandatory to assess the respective advantages and impact on host flora 
ofbroad spectrum antimicrobials in critical care. 
Evolving antibiotic susceptibility of nosocomial 
pathogens 
R.C. Spencer. P H U ,  Bristol, UK 
The emergence of antibiotic resistance in nosocomial pathogens 
continues to be an important c h c a l  problem. Gram-negative 
pathogens were more prevalent in the 1980s, and resistance has 
emerged to 3d generation cephalosporins (3GCs). quinolones and 
carbapenems. From the mid-1980s onwards, Gram-positive species 
have become more prevalent and resistance is increasing, particu- 
larly penicillin resistance in streptococci, methicillin resistance in 
staphylococci (up to 70% in coagulase-negative species causing ICU 
infections) and vancomycin resistance in enterococci. The reason for 
this increase is mulf3actorial, including inappropriate or overuse of 
broad-spectrum agents and increasing use of prosthetic materds and 
high-technology medicine. Widespread and sometimes indiscrimi- 
nate use of antibacterial agents has led to the development of mul- 
tiple drug resistance mechanisms. Faced with an alarming increase 
in resistance, rational use of antibacterials and appropriate mfec- 
tion control measures are of paramount importance. However, these 
measures can only work if supported by adequate surveillance data, 
particularly in the case of seriously ill patients where antibacterial 
therapy is mostly empirical. Surveillance must be performed at the 
local, national and international level. Most data on resistance preva- 
lence are inconsistent and hgmentary. In order to be useful, data 
should be generated by laboratories using reliable and reproducible 
testing methods, preferably reporting MICs or zone sizes, rather than 
susceptibility interpretations. In spite of the obvious problems that 
increasing resistance wiU cause, there are no formal collaborative 
surveillance studies in the developed world which will allow analysis 
of trends in resistance development. 
Clinical experience with 4th Generation 
cephalosporins in severe infections 
M. WOE. Hopital Bichnt-Claude Bernard, Paris, France 
Fourth generation cephalosporins (4GCs) are structurally related to 
3GCs but have advantages including improved membrane perme- 
ability, hgh stability and low &ty for /3-lactamases, and enhanced 
activity against Gram-positive pathogens. Only cefpirome and ce- 
fepime are widely available, but no direct comparisons have been 
made between the two. In severe infections, these agents have been 
shown to be both efficacious and safe, and at least as effective as 
ceftazidime. In ICU infections, cefpirome (n = 45) and ceftazidime 
(n = 52) gave similar clinical success rates (82% and 81% respec- 
tively. In febrile episodes in neutropenics (FNE), cefpirome and cef- 
tazidime were similar (92/127 vs 861119) although pathogens were 
more likely to be susceptible to cefpirome. Similarly, cefepime is as 
effective as ceftazidime or piperacilldgentamicin in FNE. In the 
treatment of nosocomial pneumonia, cefpirome is as effective as cef- 
tazidime, either as monotherapy (62% success for both antibiotics) or 
